Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study

Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Nader ND [verfasserIn] Hamishehkar H [verfasserIn] Naghizadeh A [verfasserIn] Shadvar K [verfasserIn] Iranpour A [verfasserIn] Sanaie S [verfasserIn] Chang F [verfasserIn] Mahmoodpoor A [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	critically ill patients dysglycemia hyperglycemia insulin glargine

Übergeordnetes Werk:	In: Diabetes, Metabolic Syndrome and Obesity - Dove Medical Press, 2009, (2020), Seite 671-678
Übergeordnetes Werk:	year:2020 ; pages:671-678

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ060629762

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ060629762
003	DE-627
005	20230501175626.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ060629762
035			\|a (DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-951
100	0		\|a Nader ND \|e verfasserin \|4 aut
245	1	0	\|a Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine
650		4	\|a critically ill patients
650		4	\|a dysglycemia
650		4	\|a hyperglycemia
650		4	\|a insulin glargine
653		0	\|a Specialties of internal medicine
700	0		\|a Hamishehkar H \|e verfasserin \|4 aut
700	0		\|a Naghizadeh A \|e verfasserin \|4 aut
700	0		\|a Shadvar K \|e verfasserin \|4 aut
700	0		\|a Iranpour A \|e verfasserin \|4 aut
700	0		\|a Sanaie S \|e verfasserin \|4 aut
700	0		\|a Chang F \|e verfasserin \|4 aut
700	0		\|a Mahmoodpoor A \|e verfasserin \|4 aut
773	0	8	\|i In \|t Diabetes, Metabolic Syndrome and Obesity \|d Dove Medical Press, 2009 \|g (2020), Seite 671-678 \|w (DE-627)60030597X \|w (DE-600)2494854-8 \|x 11787007 \|7 nnns
773	1	8	\|g year:2020 \|g pages:671-678
856	4	0	\|u https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101 \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-7007 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2020 \|h 671-678

Indexfelder

author_variant	n n nn h h hh n a na s k sk i a ia s s ss c f cf m a ma
matchkey_str	article:11787007:2020----::fetfdignuigagnogyeicnrlnrtclylptetamtetitnieaenta
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	(DE-627)DOAJ060629762 (DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101 DE-627 ger DE-627 rakwb eng RC581-951 Nader ND verfasserin aut Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine critically ill patients dysglycemia hyperglycemia insulin glargine Specialties of internal medicine Hamishehkar H verfasserin aut Naghizadeh A verfasserin aut Shadvar K verfasserin aut Iranpour A verfasserin aut Sanaie S verfasserin aut Chang F verfasserin aut Mahmoodpoor A verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 671-678 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:671-678 https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101 kostenfrei https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 671-678
spelling	(DE-627)DOAJ060629762 (DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101 DE-627 ger DE-627 rakwb eng RC581-951 Nader ND verfasserin aut Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine critically ill patients dysglycemia hyperglycemia insulin glargine Specialties of internal medicine Hamishehkar H verfasserin aut Naghizadeh A verfasserin aut Shadvar K verfasserin aut Iranpour A verfasserin aut Sanaie S verfasserin aut Chang F verfasserin aut Mahmoodpoor A verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 671-678 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:671-678 https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101 kostenfrei https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 671-678
allfields_unstemmed	(DE-627)DOAJ060629762 (DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101 DE-627 ger DE-627 rakwb eng RC581-951 Nader ND verfasserin aut Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine critically ill patients dysglycemia hyperglycemia insulin glargine Specialties of internal medicine Hamishehkar H verfasserin aut Naghizadeh A verfasserin aut Shadvar K verfasserin aut Iranpour A verfasserin aut Sanaie S verfasserin aut Chang F verfasserin aut Mahmoodpoor A verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 671-678 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:671-678 https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101 kostenfrei https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 671-678
allfieldsGer	(DE-627)DOAJ060629762 (DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101 DE-627 ger DE-627 rakwb eng RC581-951 Nader ND verfasserin aut Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine critically ill patients dysglycemia hyperglycemia insulin glargine Specialties of internal medicine Hamishehkar H verfasserin aut Naghizadeh A verfasserin aut Shadvar K verfasserin aut Iranpour A verfasserin aut Sanaie S verfasserin aut Chang F verfasserin aut Mahmoodpoor A verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 671-678 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:671-678 https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101 kostenfrei https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 671-678
allfieldsSound	(DE-627)DOAJ060629762 (DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101 DE-627 ger DE-627 rakwb eng RC581-951 Nader ND verfasserin aut Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine critically ill patients dysglycemia hyperglycemia insulin glargine Specialties of internal medicine Hamishehkar H verfasserin aut Naghizadeh A verfasserin aut Shadvar K verfasserin aut Iranpour A verfasserin aut Sanaie S verfasserin aut Chang F verfasserin aut Mahmoodpoor A verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 671-678 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:671-678 https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101 kostenfrei https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 671-678
language	English
source	In Diabetes, Metabolic Syndrome and Obesity (2020), Seite 671-678 year:2020 pages:671-678
sourceStr	In Diabetes, Metabolic Syndrome and Obesity (2020), Seite 671-678 year:2020 pages:671-678
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	critically ill patients dysglycemia hyperglycemia insulin glargine Specialties of internal medicine
isfreeaccess_bool	true
container_title	Diabetes, Metabolic Syndrome and Obesity
authorswithroles_txt_mv	Nader ND @@aut@@ Hamishehkar H @@aut@@ Naghizadeh A @@aut@@ Shadvar K @@aut@@ Iranpour A @@aut@@ Sanaie S @@aut@@ Chang F @@aut@@ Mahmoodpoor A @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	60030597X
id	DOAJ060629762
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ060629762</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501175626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ060629762</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nader ND</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140&ndash; 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann&ndash;Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P&lt; 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (&gt; 180 mg/dL) much longer among controls (P&lt; 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">critically ill patients</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dysglycemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperglycemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">insulin glargine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hamishehkar H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Naghizadeh A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shadvar K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iranpour A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sanaie S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chang F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mahmoodpoor A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2020), Seite 671-678</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:671-678</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">671-678</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Nader ND
spellingShingle	Nader ND misc RC581-951 misc critically ill patients misc dysglycemia misc hyperglycemia misc insulin glargine misc Specialties of internal medicine Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
authorStr	Nader ND
ppnlink_with_tag_str_mv	@@773@@(DE-627)60030597X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-951
illustrated	Not Illustrated
issn	11787007
topic_title	RC581-951 Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study critically ill patients dysglycemia hyperglycemia insulin glargine
topic	misc RC581-951 misc critically ill patients misc dysglycemia misc hyperglycemia misc insulin glargine misc Specialties of internal medicine
topic_unstemmed	misc RC581-951 misc critically ill patients misc dysglycemia misc hyperglycemia misc insulin glargine misc Specialties of internal medicine
topic_browse	misc RC581-951 misc critically ill patients misc dysglycemia misc hyperglycemia misc insulin glargine misc Specialties of internal medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Diabetes, Metabolic Syndrome and Obesity
hierarchy_parent_id	60030597X
hierarchy_top_title	Diabetes, Metabolic Syndrome and Obesity
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)60030597X (DE-600)2494854-8
title	Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
ctrlnum	(DE-627)DOAJ060629762 (DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101
title_full	Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
author_sort	Nader ND
journal	Diabetes, Metabolic Syndrome and Obesity
journalStr	Diabetes, Metabolic Syndrome and Obesity
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	671
author_browse	Nader ND Hamishehkar H Naghizadeh A Shadvar K Iranpour A Sanaie S Chang F Mahmoodpoor A
class	RC581-951
format_se	Elektronische Aufsätze
author-letter	Nader ND
author2-role	verfasserin
title_sort	effect of adding insulin glargine on glycemic control in critically ill patients admitted to intensive care units: a prospective randomized controlled study
callnumber	RC581-951
title_auth	Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
abstract	Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine
abstractGer	Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine
abstract_unstemmed	Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
url	https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101 https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO https://doaj.org/toc/1178-7007
remote_bool	true
author2	Hamishehkar H Naghizadeh A Shadvar K Iranpour A Sanaie S Chang F Mahmoodpoor A
author2Str	Hamishehkar H Naghizadeh A Shadvar K Iranpour A Sanaie S Chang F Mahmoodpoor A
ppnlink	60030597X
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC581-951
up_date	2024-07-03T16:07:44.259Z
_version_	1803574694911148032
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ060629762</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501175626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ060629762</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9b18ed16c0024a69a5b5cd85888f4101</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nader ND</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpooryahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140&ndash; 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann&ndash;Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P&lt; 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6+- 4.9 vs 16.4+- 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (&gt; 180 mg/dL) much longer among controls (P&lt; 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">critically ill patients</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dysglycemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperglycemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">insulin glargine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hamishehkar H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Naghizadeh A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shadvar K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iranpour A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sanaie S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chang F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mahmoodpoor A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2020), Seite 671-678</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:671-678</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">671-678</subfield></datafield></record></collection>
score	7.399996

Nicht das Richtige dabei?

Schreiben Sie uns!

Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?